LON:INDVIndivior Share Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Indivior PLC Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add GBX 64.65 +2.90 (+4.70 %) (As of 06/2/2020 02:59 AM ET) Add Compare Share Today's Range 61.85Now: GBX 64.65▼ 64.8550-Day Range 45.64MA: GBX 51.92▼ 63.5052-Week Range 32.90Now: GBX 64.65▼ 66.88Volume1.60 million shsAverage Volume2.44 million shsMarket Capitalization£473.52 millionP/E RatioN/ADividend YieldN/ABetaN/A ProfileAnalyst RatingsAdvanced ChartCompetitorsInsider TradesHeadlines Indivior PLC, together with its subsidiaries, develops, manufactures, and sells buprenorphine-based prescription drugs for the treatment of opioid dependence. The company's product pipeline focuses on treating opioid use disorder, alcohol use disorder, opiate overdose, and schizophrenia. It markets and promotes SUBLOCADE injection for subcutaneous use; and SUBOXONE sublingual film, SUBOXONE sublingual tablet, and SUBUTEX sublingual tablet, as well as sells legacy analgesic products that include Temgesic, Burpex, and Buprenex. The company operates in approximately 40 countries worldwide. Indivior PLC was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.Read More Beat the Market (BTM) Rank™ 1.0 Analyst's Opinion Consensus RatingIndivior has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 2 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of GBX 42, Indivior has a potential downside of 35.0% from its current price of GBX 64.65.Amount of Analyst CoverageIndivior has received no research coverage in the past 90 days. Previous Next 3.4 Community Rank Outperform VotesIndivior has received 549 “outperform” votes. (Add your “outperform” vote.)Underperform VotesIndivior has received 266 “underperform” votes. (Add your “underperform” vote.)Community SentimentIndivior has received 67.36% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Indivior and other stocks. Vote “Outperform” if you believe INDV will outperform the S&P 500 over the long term. Vote “Underperform” if you believe INDV will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldIndivior does not currently pay a dividend.Dividend GrowthIndivior does not have a long track record of dividend growth. Previous Next 3.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Indivior insiders have bought more of their company's stock than they have sold. Specifically, they have bought £13,200 in company stock and sold GBX 0 in company stock. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Indivior are expected to decrease by -100.00% in the coming year, from GBX 5 to GBX 0 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Indivior is -4.97, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Indivior is -4.97, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioIndivior has a P/B Ratio of 12.20. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 1.0Community Rank: 3.4Dividend Strength: 0.0Insider Behavior: 3.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.48 out of 5 stars Industry, Sector and Symbol Stock Exchange LON Industry Drugs - Generic Sub-IndustryN/A SectorMedical Current SymbolLON:INDV Previous Symbol CUSIPN/A CIKN/A Webindivior.com Phone+44-1753-217800Debt Debt-to-Equity Ratio730.77 Current Ratio1.75 Quick Ratio1.64Price-To-Earnings Trailing P/E RatioN/A Forward P/E Ratio12.93 P/E GrowthN/A Sales & Book Value Annual Sales£700 million Price / Sales0.68 Cash FlowGBX 124.49 per share Price / Cash Flow0.52 Book ValueGBX 5.30 per share Price / Book12.20Profitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous Employees915 Outstanding Shares732,435,968Market Cap£473.52 million Next Earnings Date7/29/2020 (Estimated) OptionableNot Optionable LSE:INDV Rates by TradingView Receive INDV News and Ratings via Email Sign-up to receive the latest news and ratings for INDV and its competitors with MarketBeat's FREE daily newsletter. Indivior (LON:INDV) Frequently Asked Questions How has Indivior's stock been impacted by COVID-19 (Coronavirus)? Indivior's stock was trading at GBX 46.21 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, INDV stock has increased by 39.9% and is now trading at GBX 64.65. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Indivior? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Indivior in the last year. There are currently 2 hold ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Indivior. When is Indivior's next earnings date? Indivior is scheduled to release its next quarterly earnings announcement on Wednesday, July 29th 2020. View our earnings forecast for Indivior. What price target have analysts set for INDV? 2 Wall Street analysts have issued 12 month price targets for Indivior's stock. Their forecasts range from GBX 39 to GBX 45. On average, they expect Indivior's stock price to reach GBX 42 in the next twelve months. This suggests that the stock has a possible downside of 35.0%. View analysts' price targets for Indivior. Has Indivior been receiving favorable news coverage? Media stories about INDV stock have been trending very positive on Tuesday, according to InfoTrie Sentiment. The research group identifies positive and negative news coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Indivior earned a media sentiment score of 3.5 on InfoTrie's scale. They also assigned news articles about the specialty pharmaceutical company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the stock's share price in the near future. View the latest news aboutIndivior. Who are some of Indivior's key competitors? Some companies that are related to Indivior include Patterson Companies (PDCO), Eidos Therapeutics (EIDX), Passage Bio (ZNTL), Magellan Health (MGLN), Udg Healthcare (UDG), Pacira Biosciences (PCRX), SAGE Therapeutics (SAGE), Mesoblast (MSB), Bill.com (RVMD), Cantel Medical (CMD), ProShares UltraShort DJ-UBS Commodity (CMD), USANA Health Sciences (USNA), Epizyme (EPZM), Aurinia Pharmaceuticals (AUPH) and Madrigal Pharmaceuticals (MDGL). View all competitors. What other stocks do shareholders of Indivior own? Based on aggregate information from My MarketBeat watchlists, some companies that other Indivior investors own include Futura Medical (FUM), Bigblu Broadband (BBB), Directa Plus (DCTA), Lakehouse (LAKE), Aquila Services Group (AQSG), Benchmark (BMK), Bodycote (BOY), CityFibre Infrastructure (CITY), Deltex Medical Group (DEMG) and Kingfisher (KGF). Who are Indivior's key executives? Indivior's management team includes the following people: Mr. Shaun Thaxter, CEO & Exec. DirectorMr. Mark Crossley, CFO & Exec. DirectorDr. Christian Heidbreder, Chief Scientific OfficerMr. Ingo Elfering, Chief Information & Innovation OfficerMr. Jason Thompson, VP of Investor Relations What is Indivior's stock symbol? Indivior trades on the London Stock Exchange (LON) under the ticker symbol "INDV." How do I buy shares of Indivior? Shares of INDV and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock. What is Indivior's stock price today? One share of INDV stock can currently be purchased for approximately GBX 64.65. How big of a company is Indivior? Indivior has a market capitalization of £473.52 million and generates £700 million in revenue each year. Indivior employs 915 workers across the globe. What is Indivior's official website? The official website for Indivior is indivior.com. How can I contact Indivior? Indivior's mailing address is 103-105 Bath Road, SLOUGH, SL1 3UH, United Kingdom. The specialty pharmaceutical company can be reached via phone at +44-1753-217800. This page was last updated on 6/2/2020 by MarketBeat.com Staff
